The introduction of clinical pharmacy services has led to improved therapy effectiveness and fewer adverse effects and unclear/compliant problems in cancer chemotherapy, a study has shown. Moreover, oncologists and patients highly acknowledge these pharmacist interventions, indicating a need to implement clinical pharmacy services in alternative hospitals.
New drug applications approved by US FDA as of 01 - 15 August 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
In heart failure patients with reduced ejection fraction (HFrEF) and renal impairment or hypotension, sacubitril/valsartan has been shown to be an effective angiotensin receptor and neprilysin inhibition (ARNI) intervention, reports a recent study.
Belimumab for systemic lupus erythematosus (SLE) has demonstrated a stable safety profile over 8 years of follow-up, with no new safety signal and minimal organ damage progression, according to data from an extension study involving non-American patients who completed the phase III BLISS*-52 or BLISS-76 trials.
The immunotherapeutic human papillomavirus (HPV) vaccine tipapkinogen sovacivec (TS) provided complete histologic resolution of cervical intraepithelial neoplasia (CIN) grade 2/3, offering a potential nonsurgical option for cervical precancerous lesions which could stretch to other HPV-associated precursors or cancers in the future, a new study shows.
The histone deacetylase inhibitor tucidinostat, when used in combination with exemestane for treating patients with advanced, HR-positive, HER2-negative breast cancer, prolongs progression-free survival and substantially increases overall response and clinical benefit, while having a manageable safety profile, as shown in the results of the phase III ACE trial.
On 8 August, the first town hall held by the Ministry of Health (MOH) with members of the pharmacy profession took place in Putrajaya. Over 500 pharmacists from across the country and from different areas of practice—community and hospital, public and private, academy and industry—converged to fill the auditorium for the chance to engage in direct dialogue with MOH.
Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau,
07 Aug 2019
Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.
Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1cof 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.